Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390561 | 0.99 | EPHX2 (0.51) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6387806 | 0.97 | EPHX2 (0.56) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6388900 | 0.96 | EPHX2 (0.55) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6395479 | 0.95 | NPC1 (0.55) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6390064 | 0.94 | NPC1 (0.53) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6392645 | 0.91 | CYP2C19 (0.47) | EPHX2POLBALDH1A1EPHX1NPC1 | |
| SCHEMBL6387814 | 0.91 | CYP2C19 (0.47) | EPHX2POLBALDH1A1EPHX1NPC1 | |
| SCHEMBL6389460 | 0.87 | CYP2C19 (0.44) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6394194 | 0.86 | CYP2C19 (0.43) | EPHX2KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL6395096 | 0.86 | CYP2C19 (0.43) | EPHX2POLBALDH1A1EPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | claimed |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | EPHX2 3605/4885KMT2A 4598/4885HPGD 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.